Journal article
DNA methylation estimates of immune cell abundance have prognostic potential in triple negative breast cancer
S Williams, D Korbie, M Trau, KA Avery-Kiejda, RJ Scott, B Meyer, MC Southey, RL Milne, PA Dugué, SJ Clark, C Stirzaker, R Pidsley
Clinical Epigenetics | Published : 2026
Open access
Abstract
Immune infiltration is now recognised as an important prognostic factor in triple negative breast cancer (TNBC). DNA methylation, due to its cell-type specificity, offers a promising approach for quantifying immune cell abundance as a biomarker for risk stratification. Here, we used EpiDISH, a DNA methylation-based cellular deconvolution method, to estimate immune cell proportions from genome-wide methylation data across four independent breast cancer datasets. We show that increased methylation-estimated immune cell percentage in TNBC patients is associated with improved outcomes. This highlights the potential of DNA methylation-based estimates of cell composition for prognosis in TNBC.
Related Projects (1)
Grants
Awarded by Tour de Cure